ACAmi Cuneo

Ami Cuneo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ami Cuneo has a total of 13 co-authors. Here are the top co-authors by number of shared publications:

  • Natalia Murinova

    Department of Neurology, Headache Clinic, University of Washington, 4225 Roosevelt Way NE, Seattle, WA, 98195, USA

    4 shared publications
  • Daniel Krashin

    Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle, WA, 98195, USA

    2 shared publications
  • Aysha Siddika

    Department of Neurology, Cleveland Clinic Florida, Weston, USA

    1 shared publication
  • Carrie E. Robertson

    Department of Neurology, Mayo Clinic, Rochester, USA

    1 shared publication
  • Haoran Zhou

    University of Washington

    1 shared publication
  • Jennifer I. Stern

    Department of Neurology, Mayo Clinic, Rochester, USA

    1 shared publication

Latest Publications

  • Cognitive Dysfunction in Migraine: Underlying Mechanisms and Clinical Implications

    by Ami Cuneo, Carrie E. Robertson, Jennifer I. Stern, Daniel Krashin, Aysha Siddika, Natalia Murinova


  • Corrigendum: Headache Management in Individuals with Brain Tumor

    by Ami Cuneo, Natalia Murinova

    The authors have notified the publisher of an oversight in the above article in Seminars in Neurology published in Volume 44, Number 01 (DOI: 10.1055/s-0043-1777423). Fig. 1 and Table 1 were reproduced from external sources, but the reproduction lines were inadvertently omitted from the captions. Here are the corrected captions: Fig. 1 Differential diagnosis of primary versus secondary etiologies of headache. *A list of other primary headaches is included in the ICHD-3 guidelines.2 MOH, medication overuse headache; TMD, temporomandibular disorders. Adapted from and used with permission from Mansoor AM. Frameworks for Internal Medicine. Philadelphia: Wolters Kluwer. 2019. Table 1 Characteristics of common primary headaches as compared with headache related to intracranial neoplasm, as defined by the ICHD-3 criteria.2 Adapted from Goffaux P, Fortin D. Brain tumor headaches: from bedside to bench. Neurosurgery. 2010 Aug 1;67(2):459–66 with incorporation of ICHD-3 definitions used with permission from Sagepub, copyright The International Classification of Headache Disorders, 3rd edition. Article published online: 07 May 2025 © 2025. Thieme. All rights reserved. Thieme Medical Publishers, Inc. 333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

  • Headache Management in Individuals with Brain Tumor

    by Ami Cuneo, Natalia Murinova

    Headache occurs commonly in individuals diagnosed with cerebral neoplasm. Though the features of a brain tumor-associated headache may vary, a progressive nature of headache and a change in headache phenotype from a prior primary headache disorder often are identified. Pathophysiologic mechanisms proposed for headache associated with brain tumor include headache related to traction on pain-sensitive structures, activation of central and peripheral pain processes, and complications from surgical, chemotherapeutic and/or radiotherapy treatment(s). Optimization of headache management is important for an individual's quality of life. Treatments are based upon patient-specific goals of care and may include tumor-targeted medical and surgical interventions, as well as a multimodal headache treatment approach incorporating acute and preventive medications, nutraceuticals, neuromodulation devices, behavioral interventions, anesthetic nerve blocks, and lifestyles changes.


  • The Utility of a Novel, Combined Biofeedback-Virtual Reality Device as Add-on Treatment for Chronic Migraine

    by Ami Cuneo, Robin Yang, Haoran Zhou, Ke Wang, Sarah Ba Goh, Yuntao Wang, John Raiti, Daniel Krashin, Natalia Murinova

    Objectives: To determine if the frequent use of a combined biofeedback-virtual reality device improves headache-related outcomes in chronic migraine. Materials and Methods: In this randomized, controlled pilot study, 50 adults with chronic migraine were randomized to the experimental group (frequent use of a heart rate variability biofeedback-virtual reality device plus standard medical care; n=25) or wait-list control group (standard medical care alone; n=25). The primary outcome was a reduction in mean monthly headache days between groups at 12 weeks. Secondary outcomes included mean change in acute analgesic use frequency, depression, migraine-related disability, stress, insomnia, and catastrophizing between groups at 12 weeks. Tertiary outcomes included change in heart rate variability and device-related user experience measures. Results: A statistically significant reduction in mean monthly headache days between groups was not demonstrated at 12 weeks. However, statistically significant decreases in the mean frequency of total acute analgesic use per month (65% decrease in the experimental group versus 35% decrease in the control group, PP<0.05) were shown at 12 weeks. At study completion, more than 50% of participants reported device satisfaction on a 5-level Likert scale. Discussion: Frequent use of a portable biofeedback-virtual reality device was associated with decreases in the frequency of acute analgesic use and in depression in individuals with chronic migraine. This platform holds promise as an add-on treatment for chronic migraine, especially for individuals aiming to decrease acute analgesic use or interested in nonmedication approaches.


  • Strategies for Behavioral Research in Neurology: Lessons Learned During the COVID-19 Pandemic and Applications for the Future

    by Ami Z. Cuneo, Kazi Maisha, Mia T. Minen

    Purpose of Review Behavioral therapies are proven treatments for many neurologic conditions. However, the COVID-19 pandemic has posed significant challenges for conducting behavioral research. This article aims to (1) highlight the challenges of running behavioral clinical trials during the pandemic, (2) suggest approaches to maximize generalizability of pandemic-era studies, and (3) offer strategies for successful behavioral trials beyond the pandemic. Recent Findings Thousands of clinical trials have been impacted by the COVID-19 pandemic, from undergoing protocol revisions to suspension altogether. Furthermore, for ongoing trials, recruitment of diverse populations has suffered, thereby exacerbating existing inequities in clinical research. Patient adherence and retention have been affected by a myriad of pandemic-era restraints, and medical, psychiatric, and other complications from the pandemic have the potential to have long-term effects on pandemic-era study results. Summary In the development of post-pandemic study protocols, attention should be given to designing studies that incorporate successful aspects of pre-pandemic and pandemic-era strategies to (1) broaden recruitment using new techniques, (2) improve access for diverse populations, (3) expand protocols to include virtual and in-person participation, and (4) increase patient adherence and retention.